2009
DOI: 10.1016/j.bmc.2009.09.036
|View full text |Cite
|
Sign up to set email alerts
|

3,4-Dihydropyrimido(1,2-a)indol-10(2H)-ones as potent non-peptidic inhibitors of caspase-3

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
17
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 21 publications
(18 citation statements)
references
References 25 publications
1
17
0
Order By: Relevance
“…Compounds 12 [50], 13 [51], 14 [52], 20 [53], 21 [54], 22 , 23 , 25 [55], and 24 [56] in Scheme 4 provided spectral data matching those reported in the literature. Compounds 26 , 27 [57], and 28 [58] in Scheme 5 were prepared following reported procedures.…”
Section: Methodssupporting
confidence: 55%
“…Compounds 12 [50], 13 [51], 14 [52], 20 [53], 21 [54], 22 , 23 , 25 [55], and 24 [56] in Scheme 4 provided spectral data matching those reported in the literature. Compounds 26 , 27 [57], and 28 [58] in Scheme 5 were prepared following reported procedures.…”
Section: Methodssupporting
confidence: 55%
“…Havran et al screened a library of compounds against caspase-3 and detected one lead structure 408, which was further optimized. 345 Several structurally different ligands were attached to 3,4-dihydropyrimido(1,2-α)indol-10(2H)-on scaffold, leading to the discovery of a set of potent caspase inhibitors. Compound 409 displayed the highest potency from the series but only moderate chemical stability.…”
Section: Caspase Inhibitorsmentioning
confidence: 99%
“…To better understand the binding model of synthesized inhibitors with caspase-3 and guide further design and research, compounds 11, 24, and co-crystallized inhibitor 24 were selected and docked into the active site for docking simulation studies (Fig. 3).…”
Section: Docking Studiesmentioning
confidence: 99%